Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Max Cohen

Orthopaedic Surgery Greensboro, NC Medical Doctor

NPI 1467446039 CMS profile 247305

2105 Braxton Ln Ste 101, Greensboro, NC 27408

Open in the dashboard

General payments

$5,209

251 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Max Cohen of Greensboro, NC is reported in the CMS Open Payments database as having received $5,209 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $120 2
2024 General $2,289 23
2023 General $319 25
2022 General $534 25
2021 General $285 32
2020 General $606 60
2019 General $1,056 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Max Cohen
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Max Cohen were reported at $120. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Max Cohen Orthopaedic Surgery median Middle half National median
2019 $1,056 $644 $140–$2,844 $163
2020 $606 $312 $75–$1,860 $114
2021 $285 $520 $117–$2,495 $132
2022 $534 $598 $128–$2,731 $149
2023 $319 $461 $128–$2,264 $160
2024 $2,289 $497 $134–$2,475 $164
2025 $120 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Curonix LLC $994 9 payments
  2. Medtronic USA, Inc. $824 107 payments
  3. Providence Medical Technology, Inc. $676 12 payments
  4. Piedmont Plus Innovation $627 2 payments
  5. Arthrex, Inc. $578 8 payments
  6. Medtronic, Inc. $425 52 payments
  7. Boston Scientific Corporation $339 24 payments
  8. Nevro Corp. $309 11 payments
  9. Intrinsic Therapeutics $94 1 payment
  10. Abbott Laboratories $91 4 payments
  11. Other $253 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,189 239 payments
  2. Travel and Lodging $1,998 11 payments
  3. Education $22 1 payment
Products named General payments · program years 2019–2025
  1. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $994 9 payments
  2. CAVUX Cervical Cage Medical Device $337 6 payments
  3. DTRAX Spinal System $337 6 payments
  4. BIOLOGIX Allograft Bone $337 6 payments
  5. ALLY Bone Screw $337 6 payments
  6. CAVUX Cervical Cage Orthopedic Product $169 5 payments
  7. DIVERGENCE-L $139 20 payments
  8. Omnia $131 4 payments
  9. Senza $114 4 payments
  10. O-ARM-Spine $109 18 payments
  11. Other $1,863 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Orthopedic Surgery: 203

Drug cost

$164

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 12 $164

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$113,534

Of which drugs: $87

Medicare patients

158

Average age 71

Services billed

867

97 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 32%
Diabetes 31%
Ischemic heart disease 28%
Chronic kidney disease 25%
COPD 21%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 84 $64
Injection, ketorolac tromethamine, per 15 mg J1885 Office 16 42 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record